CO5150237A1 - Metodos de aumentar el volumen oseo que comprenden la administracion de un agonista fp selectivo que no ocurre naturalmente y un compuesto de antiresorcion a un sujeto que requiere tal tratamiento - Google Patents

Metodos de aumentar el volumen oseo que comprenden la administracion de un agonista fp selectivo que no ocurre naturalmente y un compuesto de antiresorcion a un sujeto que requiere tal tratamiento

Info

Publication number
CO5150237A1
CO5150237A1 CO00015567A CO00015567A CO5150237A1 CO 5150237 A1 CO5150237 A1 CO 5150237A1 CO 00015567 A CO00015567 A CO 00015567A CO 00015567 A CO00015567 A CO 00015567A CO 5150237 A1 CO5150237 A1 CO 5150237A1
Authority
CO
Colombia
Prior art keywords
agonist
selective
administration
treatment
subject
Prior art date
Application number
CO00015567A
Other languages
English (en)
Inventor
James Richard Hartke
Mark Walden Lundy
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5150237A1 publication Critical patent/CO5150237A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con nuevos métodos para aumentar el volumen óseo que comprenden la administración de un agonista FP selectivo que no ocurre naturalmente y un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere de tal tratamiento. Esta invención se refiere adicionalmente a un método para tratar o evitar trastornos óseos que comprenden la administración de un agonista FP selectivo que no ocurre naturalmente y un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere de tal de tal tratamiento.
CO00015567A 1999-03-05 2000-03-03 Metodos de aumentar el volumen oseo que comprenden la administracion de un agonista fp selectivo que no ocurre naturalmente y un compuesto de antiresorcion a un sujeto que requiere tal tratamiento CO5150237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12292399P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
CO5150237A1 true CO5150237A1 (es) 2002-04-29

Family

ID=22405659

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00015567A CO5150237A1 (es) 1999-03-05 2000-03-03 Metodos de aumentar el volumen oseo que comprenden la administracion de un agonista fp selectivo que no ocurre naturalmente y un compuesto de antiresorcion a un sujeto que requiere tal tratamiento

Country Status (10)

Country Link
EP (1) EP1158987A1 (es)
JP (1) JP2002538122A (es)
AU (1) AU3712000A (es)
CA (1) CA2365326A1 (es)
CO (1) CO5150237A1 (es)
IL (1) IL145124A0 (es)
NO (1) NO20014193L (es)
NZ (1) NZ513827A (es)
PE (1) PE20001553A1 (es)
WO (1) WO2000051617A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
NO20014193L (no) 2001-11-05
AU3712000A (en) 2000-09-21
NO20014193D0 (no) 2001-08-29
EP1158987A1 (en) 2001-12-05
PE20001553A1 (es) 2001-01-30
NZ513827A (en) 2001-09-28
WO2000051617A1 (en) 2000-09-08
IL145124A0 (en) 2002-06-30
CA2365326A1 (en) 2000-09-08
JP2002538122A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
IL280818B (en) A methods of producing alpha-galactosidase preparations
BG102726A (en) Combined therapy for osteoporosis
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
DE69626660D1 (en) 2-alkylpyrrolidine
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
ES2549551T1 (es) Método de aumentar la dureza y la rigidez ósea y de reducir las fracturas
EP0961613A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE RESORPTION DISORDERS, INCLUDING OSTEOPOROSIS
AP9801269A0 (en) Prostaglandin agonists.
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
PL365388A1 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
EP1173470A4 (en) TREATMENT OF BONE DISORDERS BASED ON ADRENOMEDULLINE OR ADRENOMEDULLINE AGONISTS
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
EA200300461A1 (ru) Лечение т-клеточных нарушений
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
PL315127A1 (en) Deuterised biologically active substances for percutaneous administration
EP1441718A4 (en) CARBINOL FOR THE TREATMENT OF NEUROPATHIC FUNCTIONAL DISORDER
AP1896A (en) The method of treating cancer
HK1112738A1 (en) Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders
CO5150204A1 (es) Metodo de aumentar el volumen oseo que comprende la administracion de un agonista fp selectivo que no ocurre naturalmente y un agonista ep1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
CO5150237A1 (es) Metodos de aumentar el volumen oseo que comprenden la administracion de un agonista fp selectivo que no ocurre naturalmente y un compuesto de antiresorcion a un sujeto que requiere tal tratamiento
WO2004037168A3 (en) Treatment of pancreatitis with amylin